Craig Tipple

Dr Craig Tipple joined DNDi as Medical Director in May 2021 and leads our Integrated Clinical Development Sciences team comprising Drug Safety and Pharmacovigilance, Clinical Quality Assurance and Translational Science. He is the chair of the organisation’s Drug Safety and Protocol Review committees and is a member of the Global Executive Team, R&D leadership team and Scientific Review Committee. Craig has a particular interest in Patient and Community Engagement, Data-sharing and Gender-responsive R&D and is the internal senior sponsor for working groups on these topics.

Craig is a qualified medical specialist, a member of the Royal College of Physicians and holds diplomas in HIV and Genitourinary Medicine. As a doctor, he has cared for people living with HIV in London for over 12 years. He undertook his doctoral research at the Imperial College London where he studied better ways of monitoring treatment responses in people with syphilis. Craig is a vice-chair of a UK Health Research Authority Ethics Committee and an Honorary Senior Lecturer at Imperial. 

Craig has significant drug development experience from his time working at GlaxoSmithKline in their infectious diseases unit where he focused on new antibiotics and treatments for hepatitis B, Hepatitis C and HIV. Immediately prior to to joining DNDi, Craig was the Medical Director of GSK’s Phase I trials unit and led early phase R&D projects in Infectious Diseases. During the COVID-19 pandemic, Craig served as Global Clinical Development lead for an anti-viral monoclonal antibody for the disease.